Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial (Q38849759)
Jump to navigation
Jump to search
scientific article published on 27 May 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial |
scientific article published on 27 May 2016 |
Statements
1 reference
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial (English)
1 reference
Tanguy Y Seiwert
1 reference
Barbara Burtness
1 reference
Ranee Mehra
1 reference
Jared Weiss
1 reference
Raanan Berger
1 reference
Joseph Paul Eder
1 reference
Karl Heath
1 reference
Terrill McClanahan
1 reference
Jared Lunceford
1 reference
Christine Gause
1 reference
Jonathan D Cheng
1 reference
Laura Q Chow
1 reference
27 May 2016
1 reference
1 reference
17
1 reference
7
1 reference
956-965
1 reference
Identifiers
1 reference
1 reference